Research programme: retinoic acid receptor gamma agonists - Lycera

Drug Profile

Research programme: retinoic acid receptor gamma agonists - Lycera

Alternative Names: ACT therapy - Lycera; Adoptive T cell transfer therapy - Lycera; RORgamma agonist - Lycera; RORγ agonists - Lycera

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator Lycera
  • Class Antineoplastics; Cell therapies; Small molecules
  • Mechanism of Action Cell replacements; Immunostimulants; Nuclear receptor subfamily 1 group F member 3 agonists; Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Colorectal cancer

Most Recent Events

  • 19 Apr 2016 Interim pharmacodynamics data from a Preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 11 Jan 2016 Retinoic acid receptor gamma agonists licensed to Celgene
  • 09 Jun 2015 Lycera and Celgene agree to co-develop Retinoic acid receptor gamma agonists worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top